Published in Sci Transl Med on April 03, 2013
Feasibility of a New Technology for Isolating Circulating Tumour Cells (CTC-SMMiL-E) | NCT03979339
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (2014) 5.25
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 4.44
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (2015) 3.48
Single-cell RNA-seq: advances and future challenges. Nucleic Acids Res (2014) 2.06
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc (2014) 1.80
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov (2014) 1.77
Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep (2014) 1.69
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature (2016) 1.53
EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One (2015) 1.51
Acoustic separation of circulating tumor cells. Proc Natl Acad Sci U S A (2015) 1.48
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res (2015) 1.45
A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods (2015) 1.43
Inertial focusing in microfluidics. Annu Rev Biomed Eng (2014) 1.27
Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. Transl Oncol (2013) 1.26
Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip (2013) 1.23
Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nat Nanotechnol (2014) 1.18
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
Microfluidic cell sorting: a review of the advances in the separation of cells from debulking to rare cell isolation. Lab Chip (2015) 1.09
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget (2014) 1.08
Microfluidic blood cell sorting: now and beyond. Small (2014) 1.07
Inertio-elastic focusing of bioparticles in microchannels at high throughput. Nat Commun (2014) 1.06
Circulating tumor cells and DNA as liquid biopsies. Genome Med (2013) 1.06
Multivalent DNA nanospheres for enhanced capture of cancer cells in microfluidic devices. ACS Nano (2013) 1.05
Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip (2014) 1.03
Isolation and molecular characterization of circulating melanoma cells. Cell Rep (2014) 1.02
Point-of-care technologies for molecular diagnostics using a drop of blood. Trends Biotechnol (2014) 0.99
SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture. Proc Natl Acad Sci U S A (2014) 0.97
Circulating tumor cell identification by functionalized silver-gold nanorods with multicolor, super-enhanced SERS and photothermal resonances. Sci Rep (2014) 0.96
The promise of circulating tumor cell analysis in cancer management. Genome Biol (2014) 0.95
Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov (2014) 0.95
Rare cell isolation and profiling on a hybrid magnetic/size-sorting chip. Biomicrofluidics (2013) 0.94
Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells. Acc Chem Res (2014) 0.94
CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med (2014) 0.94
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 0.94
Inertial particle separation by differential equilibrium positions in a symmetrical serpentine micro-channel. Sci Rep (2014) 0.93
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med (2014) 0.93
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Res (2014) 0.92
The intersection of flow cytometry with microfluidics and microfabrication. Lab Chip (2014) 0.91
Circulating Tumor Cell Detection and Capture by Photoacoustic Flow Cytometry in Vivo and ex Vivo. Cancers (Basel) (2013) 0.91
Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater (2015) 0.91
Microfluidic techniques for high throughput single cell analysis. Curr Opin Biotechnol (2016) 0.91
The biology of circulating tumor cells. Oncogene (2015) 0.90
Nanostructured substrates for isolation of circulating tumor cells. Nano Today (2013) 0.90
Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. Analyst (2016) 0.89
Cascaded spiral microfluidic device for deterministic and high purity continuous separation of circulating tumor cells. Biomicrofluidics (2014) 0.88
Deformability of Tumor Cells versus Blood Cells. Sci Rep (2015) 0.88
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small (2014) 0.88
Lab-on-chip cytometry based on magnetoresistive sensors for bacteria detection in milk. Sensors (Basel) (2014) 0.88
Microfluidics for single-cell genetic analysis. Lab Chip (2014) 0.88
An integrated microfluidic chip system for single-cell secretion profiling of rare circulating tumor cells. Sci Rep (2014) 0.88
The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Theranostics (2014) 0.88
Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology (2015) 0.88
Physical biology in cancer. 2. The physical biology of circulating tumor cells. Am J Physiol Cell Physiol (2013) 0.87
Circulating Tumor Cells: Who is the Killer? Cancer Microenviron (2014) 0.87
Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci U S A (2016) 0.87
Fundamentals and application of magnetic particles in cell isolation and enrichment: a review. Rep Prog Phys (2014) 0.86
Alternating current electrohydrodynamics in microsystems: Pushing biomolecules and cells around on surfaces. Biomicrofluidics (2015) 0.86
Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo. Onco Targets Ther (2014) 0.86
Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance. Nanomedicine (2013) 0.86
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. Oncotarget (2016) 0.86
Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria. Cell Death Dis (2013) 0.85
Track-etched magnetic micropores for immunomagnetic isolation of pathogens. Adv Healthc Mater (2014) 0.85
Staged Inertial Microfluidic Focusing for Complex Fluid Enrichment. RSC Adv (2015) 0.85
Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Sci (2015) 0.84
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip (2013) 0.84
Nanotechnology: emerging tools for biology and medicine. Genes Dev (2013) 0.84
Cancer: Staying together on the road to metastasis. Nature (2014) 0.84
Continuous Flow Microfluidic Bioparticle Concentrator. Sci Rep (2015) 0.84
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer (2016) 0.84
An Integrated Platform for Isolation, Processing, and Mass Spectrometry-based Proteomic Profiling of Rare Cells in Whole Blood. Mol Cell Proteomics (2015) 0.83
Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell. PLoS One (2014) 0.83
Development of a new rapid isolation device for circulating tumor cells (CTCs) using 3D palladium filter and its application for genetic analysis. PLoS One (2014) 0.83
Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings. J Am Coll Surg (2015) 0.83
Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells. Sci Rep (2016) 0.82
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res (2015) 0.82
Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. Cancer Res (2015) 0.82
Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis. Cancers (Basel) (2013) 0.82
Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells. Sci Rep (2014) 0.82
Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A (2015) 0.82
Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers (Basel) (2013) 0.81
Circulating cancer stem cells: the importance to select. Chin J Cancer Res (2015) 0.81
A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One (2015) 0.81
High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. PLoS One (2015) 0.81
Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System. Front Neurol (2015) 0.80
Microchip-based detection of magnetically labeled cancer biomarkers. Adv Drug Deliv Rev (2013) 0.80
Single-cell analyses of circulating tumor cells. Cancer Biol Med (2015) 0.80
Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep (2016) 0.80
Sensitive and Specific Biomimetic Lipid Coated Microfluidics to Isolate Viable Circulating Tumor Cells and Microemboli for Cancer Detection. PLoS One (2016) 0.80
Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit Rev Clin Lab Sci (2015) 0.80
Microfluidic impedance cytometry of tumour cells in blood. Biomicrofluidics (2014) 0.80
In Vivo Long-Term Monitoring of Circulating Tumor Cells Fluctuation during Medical Interventions. PLoS One (2015) 0.80
Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget (2016) 0.80
A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget (2016) 0.79
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. Front Oncol (2015) 0.79
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.79
Screening and Molecular Analysis of Single Circulating Tumor Cells Using Micromagnet Array. Sci Rep (2015) 0.79
Multivalent conjugation of antibody to dendrimers for the enhanced capture and regulation on colon cancer cells. Sci Rep (2015) 0.79
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
High gradient magnetic cell separation with MACS. Cytometry (1990) 6.69
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Continuous particle separation through deterministic lateral displacement. Science (2004) 5.60
Continuous inertial focusing, ordering, and separation of particles in microchannels. Proc Natl Acad Sci U S A (2007) 4.44
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci Transl Med (2012) 2.82
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol (2012) 2.21
Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng (2009) 2.16
The evolving war on cancer. Cell (2011) 2.02
Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol (2004) 1.83
A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev (2009) 1.73
A microfluidics approach for the isolation of nucleated red blood cells (NRBCs) from the peripheral blood of pregnant women. Prenat Diagn (2008) 1.63
High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem (2011) 1.62
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res (2008) 1.59
Computational design optimization for microfluidic magnetophoresis. Biomicrofluidics (2011) 1.23
Circulating tumor cells: getting more from less. Sci Transl Med (2012) 1.07
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device. Nat Biotechnol (2002) 5.37
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell (2007) 5.19
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
Continuous inertial focusing, ordering, and separation of particles in microchannels. Proc Natl Acad Sci U S A (2007) 4.44
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res (2012) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74